Essien Research Lab
Welcome to the PharmacoEquity, Advocacy, Research, and Leadership Lab
The PEARL Lab is a health equity and services research lab focusing on improving equitable access to novel medications and technologies, especially for treating heart diseases.
Recent News
California Academic Geriatrics Institutions (CAGI) Conference 2025
Dr. Michelle Keller from the University of Southern California (USC), Jasmyn J. Tang, and Valerie Nguyen presented their project: Disparities in Anti-Dementia Drug Used in ADRD by Specialist at the California Academic Geriatrics Institutions Conference on May 30 at the University of California, Irvine (UCI).
American Heart Association EPI Lifestyle Scientific Sessions 2025
Dr. Utibe Essien and Jasmyn J. Tang presented 2 projects at the AHA EPI conference in New Orleans, Louisiana, entitled: "Race and Ethnicity and Oral Anticoagulation Adherence in Older Adults with Atrial Fibrillation: A Nationwide Study and Neighborhood-Level Racial and Ethnic Residential Segregation" and "Incidence of Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA)."
UCLA DoM Research Day 2024
Showcasing PEARL Lab's research and collaboration, Jasmyn J. Tang presented on the "Association of Race and Ethnicity with Stroke and Mortality Outcomes in Atrial Fibrillation", comparing incidences of stroke and mortality across demographic groups of VA patients with Atrial Fibrillation (AF).
Outstanding Junior Investigator of the Year
Congratulations to Dr. Utibe Essien for winning the 2024 Society of General Internal Medicine (SGIM) Junior Investigator of the Year award!
Addressing Disparities in Accessing Antiobesity Medications
On the final day of the American Diabetes Association 84th Scientific Sessions, Dr. Essien reviewed disparities in obesity treatment, and which specific populations are more likely to experience obesity in the United States.
2024 Pharmacoequity Conference
The 3rd annual Pharmacoequity Conference took place on May 3, 2024 at the University of Pittsburgh, showcasing the diverse and ever growing pharmacoequity research and policy.
